(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Vesikari T et al. | Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. | 2012 | Hum Vaccin Immunother | pmid:22906943 |
Hwang SM et al. | Comparison of the adverse events associated with MF59-adjuvanted and non-adjuvanted H1N1 vaccines in healthy young male Korean soldiers. | 2012 | Jpn. J. Infect. Dis. | pmid:22627298 |
Siegrist CA et al. | Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. | 2012 | Antivir. Ther. (Lond.) | pmid:22544169 |
Yang M et al. | MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1+ tumor immunity in mice. | 2012 | Int. Immunopharmacol. | pmid:22595192 |
Cabrera-Vique C et al. | Bioactive compounds and nutritional significance of virgin argan oil--an edible oil with potential as a functional food. | 2012 | Nutr. Rev. | pmid:22537213 |
Sarpietro MG et al. | Squalenoyl prodrug of paclitaxel: synthesis and evaluation of its incorporation in phospholipid bilayers. | 2012 | Int J Pharm | pmid:22728161 |
Wu S et al. | Engineering triterpene metabolism in tobacco. | 2012 | Planta | pmid:22729821 |
Langley JM et al. | Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity. | 2012 | Pediatr. Infect. Dis. J. | pmid:22801094 |
Fox CB et al. | Effects on immunogenicity by formulations of emulsion-based adjuvants for malaria vaccines. | 2012 | Clin. Vaccine Immunol. | pmid:22896687 |
Reynales H et al. | A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. | 2012 | Vaccine | pmid:22902681 |